1312566-06-5

Basic information

• Product Name: (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine-4-carboxylate
• Synonyms: (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine-4-carboxylate
• CAS NO: 1312566-06-5
• Molecular Weight: 442.558
• Mol File: 1312566-06-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine-4-carboxylate(1312566-06-5)
• EPA Substance Registry System: (S)-tert-butyl 2-(4-(diphenylmethyleneamino)phenyl)morpholine-4-carboxylate(1312566-06-5)

Safety Data

• Hazardous Substances Data: 1312566-06-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 920798-90-9 (S)-2-(4-bromo-phenyl)-morpholine 
• 83555-73-1 (RS)-2-(4-bromophenyl)morpholine 
• 1013-88-3 Benzophenone imine 
• 1131220-37-5 (S)-tert-butyl 2-(4-bromophenyl)morpholine-4-carboxylate 

Downstream Products

• 1357267-39-0 (S)-1-(4-fluorobenzyl)-3-(4-(morpholin-2-yl)phenyl)urea hydrochloride 
• 1357267-37-8 (S)-tert-butyl 2-(4-(6-(2,2,2-trifluoroethoxy)nicotinamido)phenyl)morpholine-4-carboxylate 
• 1312564-19-4 (S)-N-(4-(morpholin-2-yl)phenyl)-6-(2,2,2-trifluoroethoxy)nicotinamide hydrochloride 
• 1576038-91-9 (S)-tert-butyl 2-(4-(1-(5-bromopyridin-2-yl)-1H-1,2,3-triazole-4-carboxamido)phenyl)morpholine-4-carboxylate 
• 1576038-85-1 (S)-tert-butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-1,2,4-triazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1576038-51-1 (S)-tert-butyl 2-(4-(2-phenyl-2H-1,2,3-triazole-4-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-72-9 (S)-tert-butyl 2-(4-(1-(3-chloropyrazin-2-yl)-1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-70-7 (S)-tert-butyl 2-(4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-68-3 (S)-tert-butyl 2-(4-(1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-66-1 (S)-tert-butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-56-9 (S)-tert-butyl 2-(4-(3-(3-(difluoromethoxy)phenyl)-1-ethyl-1H-pyrazole-5-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-54-7 (S)-tert-butyl 2-(4-(5-(3-(difluoromethoxy)phenyl)-1-ethyl-1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-51-4 (S)-tert-butyl 2-(4-(3-(3-(difluoromethoxy)phenyl)-1H-pyrazole-5-carboxamido)phenyl)morpholine-4-carboxylate 
• 1415829-26-3 (S)-tert-butyl 2-(4-(5-phenyl-1H-pyrazole-3-carboxamido)phenyl)morpholine-4-carboxylate 

Relevant articles and documents

TRIAZOLE CARBOXAMIDES AND USES THEREOF

The invention relates to compounds of formula wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen;X1 is —N═ or CH

TRIAZOLE CARBOXAMIDE DERIVATIVES

The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N=

PYRAZOLE DERIVATIVES

The invention relates to compounds of formula wherein R1 is hydrogen or phenyl, optionally substitutes by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen or lower alkyl or is phenyl optionally substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; R4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.